1. Home
  2. VLRS vs GYRE Comparison

VLRS vs GYRE Comparison

Compare VLRS & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VLRS
  • GYRE
  • Stock Information
  • Founded
  • VLRS 2005
  • GYRE 2002
  • Country
  • VLRS Mexico
  • GYRE United States
  • Employees
  • VLRS N/A
  • GYRE N/A
  • Industry
  • VLRS Air Freight/Delivery Services
  • GYRE Biotechnology: Pharmaceutical Preparations
  • Sector
  • VLRS Consumer Discretionary
  • GYRE Health Care
  • Exchange
  • VLRS Nasdaq
  • GYRE Nasdaq
  • Market Cap
  • VLRS 816.9M
  • GYRE 755.7M
  • IPO Year
  • VLRS N/A
  • GYRE N/A
  • Fundamental
  • Price
  • VLRS $6.41
  • GYRE $7.26
  • Analyst Decision
  • VLRS Buy
  • GYRE Strong Buy
  • Analyst Count
  • VLRS 6
  • GYRE 2
  • Target Price
  • VLRS $8.43
  • GYRE $17.00
  • AVG Volume (30 Days)
  • VLRS 613.8K
  • GYRE 85.0K
  • Earning Date
  • VLRS 10-27-2025
  • GYRE 11-13-2025
  • Dividend Yield
  • VLRS N/A
  • GYRE N/A
  • EPS Growth
  • VLRS N/A
  • GYRE N/A
  • EPS
  • VLRS N/A
  • GYRE 0.02
  • Revenue
  • VLRS $2,990,876,000.00
  • GYRE $102,189,000.00
  • Revenue This Year
  • VLRS N/A
  • GYRE $15.25
  • Revenue Next Year
  • VLRS $12.26
  • GYRE $33.14
  • P/E Ratio
  • VLRS N/A
  • GYRE $429.99
  • Revenue Growth
  • VLRS N/A
  • GYRE N/A
  • 52 Week Low
  • VLRS $3.49
  • GYRE $6.11
  • 52 Week High
  • VLRS $9.00
  • GYRE $19.00
  • Technical
  • Relative Strength Index (RSI)
  • VLRS 42.17
  • GYRE 40.67
  • Support Level
  • VLRS $6.29
  • GYRE $7.45
  • Resistance Level
  • VLRS $6.68
  • GYRE $8.37
  • Average True Range (ATR)
  • VLRS 0.31
  • GYRE 0.39
  • MACD
  • VLRS -0.08
  • GYRE -0.11
  • Stochastic Oscillator
  • VLRS 8.44
  • GYRE 0.46

About VLRS Controladora Vuela Compania de Aviacion S.A.B. de C.V.

Controladora Vuela Compania de Aviacion SAB de CV is a low-cost airline flying to Mexico, the United States, Central, and South America. It uses promotional fares to stimulate demand, and the base fares are priced to compete with long-distance bus fares in Mexico. Revenues from the air transportation of passengers are recognized earlier when the service is provided or when the non-refundable ticket expires on the date of the scheduled travel. Non-passenger revenues include revenues generated from other non-passenger services and cargo services. The Company has two geographic areas identified as domestic (Mexico) and international (United States of America, Central America, and South America).

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: